Top

Reviews in Endocrine and Metabolic Disorders

Published in:

Open Access 01-09-2021 | Carcinoid Tumor

Chemotherapy in NEN: still has a role?

Authors: Paula Espinosa-Olarte, Anna La Salvia, Maria C. Riesco-Martinez, Beatriz Anton-Pascual, Rocio Garcia-Carbonero

Published in: Reviews in Endocrine and Metabolic Disorders | Issue 3/2021

Abstract

Neuroendocrine neoplasms (NENs) comprise a broad spectrum of tumors with widely variable biological and clinical behavior. Primary tumor site, extent of disease, tumor differentiation and expression of so matostatin receptors, proliferation and growth rates are the major prognostic factors that determine the therapeutic strategy. Treatment options for advanced disease have considerably expanded in recent years, particularly for well differentiated tumors (NETs). Novel drugs approved over the past decade in this context include somatostatin analogues and ¹⁷⁷Lu-oxodotreotide for somatostatin-receptor-positive gastroenteropancreatic (GEP) NETs, sunitinib for pancreatic NETs (P-NETs), and everolimus for P-NETs and non-functioning lung or gastrointestinal NETs. Nevertheless, chemotherapy remains an essential component of the treatment armamentarium of patients with NENs, particularly of patients with P-NETs or those with bulky, symptomatic or rapidly progressive tumors (generally G3 or high-G2 NENs). In this manuscript we will comprehensively review available evidence related to the use of chemotherapy in lung and GEP NENs and will critically discuss its role in the treatment algorithm of this family of neoplasms.

Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, et al. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncol. 2017;3(10):1335–42.PubMedPubMedCentralCrossRef

Nagtegaal ID, Odze RD, Klimstra D, Paradis V, Rugge M, Schirmacher P, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020;76(2):182–8.PubMedCrossRef

Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, et al. The 2015 World Health Organization Classification of Lung Tumors. J Thorac Oncol. 2015;10(9):1243–60.PubMedCrossRef

Hofland J, Kaltsas G, de Herder WW. Advances in the Diagnosis and Management of Well-Differentiated Neuroendocrine Neoplasms. Endocr Rev. 2020;41(2):371–403.PubMedCentralCrossRef

Rinke A, Müller H-H, Schade-Brittinger C, Klose K-J, Barth P, Wied M, et al. Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group. J Clin Oncol. 2009;27:4656–63.PubMedCrossRef

Caplin ME, Pavel M, Ćwikła JB, Phan AT, Raderer M, Sedláčková E, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371(3):224–33.PubMedCrossRef

Eric R, Laetitia D, Jean-Luc R, Yung-Jue B, Ivan B, Catherine L-B, et al. Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors. N Engl J Med. 2011;364:501–13.CrossRef

Yao JC, Shah MH, Tetsuhide I, Catherine L-B, Wolin EM, Cutsem EV. Everolimus for Advanced Pancreatic Neuroendocrine Tumors. N Engl J Med. 2011;364:514–23.PubMedPubMedCentralCrossRef

Yao JC, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E, et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. The Lancet. 2016;387(10022):968–77.CrossRef

10.

Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med. 2017;376:125–35.PubMedPubMedCentralCrossRef

11.

Moertel CG, Hanley JA, Johnson LA. Streptozocin Alone Compared with Streptozocin plus Fluorouracil in the Treatment of Advanced Islet-Cell Carcinoma. N Engl J Med. 1980;303(21):1189–94.PubMedCrossRef

12.

Moertel C, Lefkopoulo M, Lipsitz S, Hahn R, Klaassen D. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med. 1992;326(8):519–23.PubMedCrossRef

13.

Meyer T, Qian W, Caplin ME, Armstrong G, Lao-Sirieix S-H, Hardy R, et al. Capecitabine and streptozocin±cisplatin in advanced gastroenteropancreatic neuroendocrine tumours. Eur J Cancer. 2014;50(5):902–11.PubMedCrossRef

14.

Ducreux M, Dahan L, Smith D, O’Toole D, Lepère C, Dromain C, et al. Bevacizumab combined with 5-FU/streptozocin in patients with progressive metastatic well-differentiated pancreatic endocrine tumours (BETTER trial) – A phase II non-randomised trial. Eur J Cancer. 2014;50(18):3098–106.PubMedCrossRef

15.

Ramanathan RK, Cnaan A, Hahn RG, Carbone PP, Haller DG. Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282. Ann Oncol. 2001;12(8):1139–43.

16.

Bajetta E, Ferrari L, Procopio G, Catena L, Ferrario E, Martinetti A, et al. Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumours. Ann Oncol. 2002;13(4):614–21.PubMedCrossRef

17.

Bajetta E, Rimassa L, Carnaghi C, Seregni E, Ferrari L, Bartolomeo MD, et al. 5-fluorouracil, dacarbazine, and epirubicin in the treatment of patients with neuroendocrine tumors. Am Cancer Soc. 1998;83(2):372–8.

18.

Kulke MH, Hornick JL, Frauenhoffer C, Hooshmand S, Ryan DP, Enzinger PC, et al. O6-Methylguanine DNA Methyltransferase Deficiency and Response to Temozolomide-Based Therapy in Patients with Neuroendocrine Tumors. Clin Cancer Res. 2009;15(1):338–45.PubMedPubMedCentralCrossRef

19.

Cives M, Ghayouri M, Morse B, Brelsford M, Black M, Rizzo A, et al. Analysis of potential response predictors to capecitabine/temozolomide in metastatic pancreatic neuroendocrine tumors. Endocr Relat Cancer. 2016;23(9):759–67.PubMedCrossRef

20.

Kulke MH, Stuart K, Enzinger PC, Ryan DP, Clark JW, Muzikansky A, et al. Phase II Study of Temozolomide and Thalidomide in Patients With Metastatic Neuroendocrine Tumors. J Clin Oncol. 2006;24(3):401–6.PubMedCrossRef

21.

Chan JA, Stuart K, Earle CC, Clark JW, Bhargava P, Miksad R, et al. Prospective Study of Bevacizumab Plus Temozolomide in Patients With Advanced Neuroendocrine Tumors. J Clin Oncol. 2012;30(24):2963–8.PubMedPubMedCentralCrossRef

22.

Chan JA, Blaszkowsky L, Stuart K, Zhu AX, Allen J, Wadlow R, et al. A prospective, phase 1/2 study of everolimus and temozolomide in patients with advanced pancreatic neuroendocrine tumor: Everolimus Temozolomide in Pancreatic NET. Cancer. 2013;119(17):3212–8.PubMedCrossRef

23.

Strosberg JR, Fine RL, Choi J, Nasir A, Coppola D, Chen D-T, et al. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer. 2011;117(2):268–75.PubMedCrossRef

24.

Ganetsky A, Adel NG, Do KG, Reidy DL. The efficacy of capecitabine and temozolomide for the treatment of metastatic neuroendocrine tumors: Memorial Sloan-Kettering Cancer Center experience. J Clin Oncol. 2012;30(4_suppl):363–363.

25.

Saif MW, Kaley K, Brennan M, Garcon MC, Rodriguez G, Rodriguez T. A Retrospective Study of Capecitabine/Temozolomide (CAPTEM) Regimen in the Treatment of Metastatic Pancreatic Neuroendocrine Tumors (pNETs) after Failing Previous Therapy. J Pancreas Online. 2013;14(5):498–501.

26.

Fine RL, Gulati AP, Krantz BA, Moss RA, Schreibman S, Tsushima DA, et al. Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience. Cancer Chemother Pharmacol. 2013;71(3):663–70.PubMedCrossRef

27.

Abbasi S, Kashashna A, Albaba H. Efficacy of Capecitabine and Temozolomide Combination in Well-Differentiated Neuroendocrine Tumors: Jordan Experience. Pancreas. 2014;43(8):1303–5.PubMedCrossRef

28.

Peixoto RD, Noonan KL, Pavlovich P, Kennecke HF, Lim HJ. Outcomes of patients treated with capecitabine and temozolamide for advanced pancreatic neuroendocrine tumors (PNETs) and non-PNETs. J Gastrointest Oncol. 2014;5(4):247–52.PubMedPubMedCentral

29.

Ramirez RA, Beyer DT, Chauhan A, Boudreaux JP, Wang Y, Woltering EA. The Role of Capecitabine/Temozolomide in Metastatic Neuroendocrine Tumors. Oncologist. 2016;21(6):671–5.PubMedPubMedCentralCrossRef

30.

Crespo G, Jiménez-Fonseca P, Custodio A, López C, Carmona-Bayonas A, Alonso V, et al. Capecitabine and temozolomide in grade 1/2 neuroendocrine tumors: a Spanish multicenter experience. Future Oncol. 2017;13(7):615–24.PubMedCrossRef

31.

Kunz PL, Catalano PJ, Nimeiri H, Fisher GA, Longacre TA, Suarez CJ, et al. A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: A trial of the ECOG-ACRIN Cancer Research Group (E2211). J Clin Oncol. 2018;36(15_suppl):4004–4004.

32.

Chatzellis E, Angelousi A, Daskalakis K, Tsoli M, Alexandraki KI, Wachuła E, et al. Activity and Safety of Standard and Prolonged Capecitabine/Temozolomide Administration in Patients with Advanced Neuroendocrine Neoplasms. Neuroendocrinology. 2019;109(4):333–45.PubMedCrossRef

33.

Lamarca A, Barriuso J, McNamara MG, Hubner RA, Manoharan P, Mansoor W, et al. Temozolomide-Capecitabine Chemotherapy for Neuroendocrine Neoplasms: The Dilemma of Treatment Duration. Neuroendocrinology. 2020;110:155–7.PubMedCrossRef

34.

Claringbold PG, Price RA, Turner JH. Phase I-II Study of Radiopeptide 177Lu-Octreotate in Combination with Capecitabine and Temozolomide in Advanced Low-Grade Neuroendocrine Tumors. Cancer Biother Radiopharm. 2012;27(9):561–9.PubMed

35.

Claringbold PG, Turner JH. Pancreatic Neuroendocrine Tumor Control: Durable Objective Response to Combination 177Lu-Octreotate-Capecitabine-Temozolomide Radiopeptide Chemotherapy. Neuroendocrinology. 2016;103(5):432–9.PubMedCrossRef

36.

Pavlakis N, Ransom D, Wyld D, Sjoquist K, Asher R, Gebski V, et al. Australasian Gastrointestinal Trials Group (AGITG) CONTROL NET Study: Phase II study evaluating the activity of 177 Lu-Octreotate peptide receptor radionuclide therapy (LuTate PRRT) and capecitabine, temozolomide CAPTEM)—First results for pancreas and updated midgut neuroendocrine tumors (pNETS, mNETS). J Clin Oncol. 2020;38(15_suppl):4608–4608.

37.

Uboha NV, Lubner SJ, LoConte NK, Mulkerin DL, Eickhoff JC, Deming DA. Phase 1 dose escalation trial of TAS-102 (trifluridine/tipiracil) and temozolomide in the treatment of advanced neuroendocrine tumors. Invest New Drugs. 2020;38(5):1520–5.PubMedCrossRef

38.

Brixi-Benmansour H, Jouve J-L, Mitry E, Bonnetain F, Landi B, Hentic O, et al. Phase II study of first-line FOLFIRI for progressive metastatic well-differentiated pancreatic endocrine carcinoma. Dig Liver Dis. 2011;43(11):912–6.PubMedCrossRef

39.

Ducreux MP, Boige V, Leboulleux S, Malka D, Kergoat P, Dromain C, et al. A Phase II Study of Irinotecan with 5-Fluorouracil and Leucovorin in Patients with Pretreated Gastroenteropancreatic Well-Differentiated Endocrine Carcinomas. Oncology. 2006;70(2):134–40.PubMedCrossRef

40.

Spada F, Antonuzzo L, Marconcini R, Radice D, Antonuzzo A, Ricci S, et al. Oxaliplatin-Based Chemotherapy in Advanced Neuroendocrine Tumors: Clinical Outcomes and Preliminary Correlation with Biological Factors. Neuroendocrinology. 2016;103(6):806–14.PubMedCrossRef

41.

Moertel CG, Kvols LK, O’Connell MJ, Rubin J. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer. 1991;68(2):227–32.

42.

Fjällskog ML, Granberg DP, Welin SL, Eriksson C, Oberg KE, Janson ET, Eriksson BK. Treatment with cisplatin and etoposide in patients withneuroendocrine tumors. Cancer. 2001;92(5):1101–7.PubMedCrossRef

43.

Bajetta E, Catena L, Procopio G, De Dosso S, Bichisao E, Ferrari L, et al. Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours? Cancer Chemother Pharmacol. 2007;59(5):637–42.PubMedCrossRef

44.

Kunz PL, Balise RR, Fehrenbacher L, Pan M, Venook AP, Fisher GA, et al. Oxaliplatin-Fluoropyrimidine Chemotherapy Plus Bevacizumab in Advanced Neuroendocrine Tumors: An Analysis of 2 Phase II Trials. Pancreas. 2016;45(10):1394–400.PubMedCrossRef

45.

Grande E, Lopez C, Alonso Gordoa T, Benavent M, Capdevila J, Teulé A, et al. SUNitinib with EVOfosfamide (TH-302) for G1/G2 metastatic pancreatic neuroendocrine tumours (pNETs) naïve for systemic treatment. The SUNEVO phase II trial of the Spanish task force group for neuroendocrine and endocrine tumours (GETNE). Ann Oncol. 2019;30:v566.

46.

Randomized Phase 2 Trial Of Two Chemotherapy Regimens Plus Or Minus Bevacizumab In Patients With Well Differentiated Pancreatic Neuroendocrine Tumors (NCT03351296). Available from: https://clinicaltrials.gov.

47.

Randomized Open Label Study to Compare the Efficacy and Safety of Everolimus Followed by Chemotherapy With Streptozotocin- Fluorouracilo (STZ-5FU) Upon Progression or the Reverse Sequence, in Advanced Progressive Pancreatic NETs (pNETs) (NCT02246127). Available from: https://clinicaltrials.gov.

48.

Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase II (NCT02230176). Available from: https://clinicaltrials.gov.

49.

A Prospective, Randomised, Controlled, Open-label, Multicentre Phase III Study to Evaluate Efficacy and Safety of Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-Edotreotide Compared to Targeted Molecular Therapy With Everolimus in Patients With Inoperable, Progressive, Somatostatin Receptor-positive (SSTR+), Neuroendocrine Tumours of Gastroenteric or Pancreatic Origin (GEP-NET) (NCT03049189). Available from: https://clinicaltrials.gov.

50.

Fine RL, Gulati AP, Tsushima D, Mowatt KB, Oprescu A, Bruce JN, et al. Prospective phase II study of capecitabine and temozolomide (CAPTEM) for progressive, moderately, and well-differentiated metastatic neuroendocrine tumors. J Clin Oncol. 2014;32(3_suppl):179–179.

51.

Berruti A, Fazio N, Ferrero A, Brizzi MP, Volante M, Nobili E, et al. Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the xelbevoct study. BMC Cancer. 2014;14(1):184.PubMedPubMedCentralCrossRef

52.

Moertel C, Hanley JA. Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer Clin Trials. 1979;2(4):327–34.PubMed

53.

Engstrom PF, Lavin PT, Folsch E, Douglass HO. Streptozocin plus Fluorouracil versus Doxorubicin therapy for metastatic carcinoid tumor. J Clin Oncol. 1984;2(11):1255–9.PubMedCrossRef

54.

Sun W, Lipsitz S, Catalano P, Mailliard JA, Haller DG. Phase II/III Study of Doxorubicin With Fluorouracil Compared With Streptozocin With Fluorouracil or Dacarbazine in the Treatment of Advanced Carcinoid Tumors: Eastern Cooperative Oncology Group Study E1281. J Clin Oncol. 2005;23(22):4897–904.PubMedCrossRef

55.

Dahan L, Bonnetain F, Rougier P, Raoul J-L, Gamelin E, Etienne P-L, et al. Phase III trial of chemotherapy using 5-fluorouracil and streptozotocin compared with interferon a for advanced carcinoid tumors: FNCLCC–FFCD 9710. Endocr Relat Cancer. 2009;16:1351–61.PubMedCrossRef

56.

Bukowski R, Tangen C, Peterson R, Taylor S, Rinehart J, Eyre H, et al. Phase II trial of dimethyltriazenoimidazole carboxamide in patients with metastatic carcinoid. A Southwest Oncology Group study Cancer. 1994;73(5):1505–8.

57.

Turner NC, Strauss SJ, Sarker D, Gillmore R, Kirkwood A, Hackshaw A, et al. Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours. Br J Cancer. 2010;102(7):1106–12.PubMedPubMedCentralCrossRef

58.

Medley L, Morel AN, Farrugia D, Reed N, Hayward N, Davies JM, et al. Phase II study of single agent capecitabine in the treatment of metastatic non-pancreatic neuroendocrine tumours. Br J Cancer. 2011;104(7):1067–70.PubMedPubMedCentralCrossRef

59.

Mitry E, Walter T, Baudin E, Kurtz J-E, Ruszniewski P, Dominguez-Tinajero S, et al. Bevacizumab plus capecitabine in patients with progressive advanced well-differentiated neuroendocrine tumors of the gastro-intestinal (GI-NETs) tract (BETTER trial) – A phase II non-randomised trial. Eur J Cancer. 2014;50(18):3107–15.PubMedCrossRef

60.

Ekeblad S, Sundin A, Janson ET, Welin S, Granberg D, Kindmark H, et al. Temozolomide as Monotherapy Is Effective in Treatment of Advanced Malignant Neuroendocrine Tumors. Clin Cancer Res. 2007;13(10):2986–91.PubMedCrossRef

61.

Ferrolla P, Berruti A, Spada F, Brizzi MP, Ibrahim T, Colao A, et al. Lanreotide autogel (LAN) and temozolomide (TMZ) combination therapy in progressive thoracic neuroendocrine tumours (TNETs): ATLANT study results. Ann Oncol 2020 31 Suppl4 S711-S724 101016/annonc/annonc281.

62.

Papaxoinis G, Kordatou Z, McCallum L, Nasralla M, Lamarca A, Backen A, et al. Capecitabine and Temozolomide in Patients with Advanced Pulmonary Carcinoid Tumours. Neuroendocrinology. 2020;110(5):413-421; Al-Toubah T, Morse B, Strosberg J. Capecitabine and Temozolomide in Advanced Lung Neuroendocrine Neoplasms. Oncologist. 2020;25(1):e48-e52. https://doi.org/10.1634/theoncologist.2019-0361. Epub 2019 Aug 27

63.

Granberg D, Eriksson B, Wilander E, Grimfjärd P, Fjällskog M-L, Öberg K, et al. Experience in treatment of metastatic pulmonary carcinoid tumors. Ann Oncol. 2001;12(10):1383–91.PubMedCrossRef

64.

Forde PM, Hooker CM, Boikos SA, Petrini I, Giaccone G, Rudin CM, et al. Systemic Therapy, Clinical Outcomes, and Overall Survival in Locally Advanced or Metastatic Pulmonary Carcinoid: A Brief Report. J Thorac Oncol. 2014;9(3):414–8.PubMedPubMedCentralCrossRef

65.

Chong CR, Wirth LJ, Nishino M, Chen AB, Sholl LM, Kulke MH, et al. Chemotherapy for locally advanced and metastatic pulmonary carcinoid tumors. Lung Cancer. 2014;86(2):241–6.PubMedCrossRef

66.

Lamarca A, Elliott E, Barriuso J, Backen A, McNamara MG, Hubner R, et al. Chemotherapy for advanced non-pancreatic well-differentiated neuroendocrine tumours of the gastrointestinal tract, a systematic review and meta-analysis: A lost cause? Cancer Treat Rev. 2016;44:26–41.PubMedCrossRef

67.

Garcia-Carbonero R, Sorbye H, Baudin E, Raymond E, Wiedenmann B, Niederle B, et al. ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas. Neuroendocrinology. 2016;103(2):186–94.PubMedCrossRef

68.

Garcia-Carbonero R, Rinke A, Valle JW, Fazio N, Caplin M, Gorbounova V, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy - Chemotherapy. Neuroendocrinology. 2017;105(3):281–94.PubMedCrossRef

69.

Sorbye H, Welin S, Langer SW, Vestermark LW, Holt N, Osterlund P, et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study. Ann Oncol. 2013;24(1):152–60.PubMedCrossRef

70.

Mitry E, Baudin E, Ducreux M, Sabourin J-C, Rufié P, Aparicio T, et al. Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer. 1999;81(8):1351–5.PubMedPubMedCentralCrossRef

71.

Iwasa S, Morizane C, Okusaka T, Ueno H, Ikeda M, Kondo S, et al. Cisplatin and Etoposide as First-line Chemotherapy for Poorly Differentiated Neuroendocrine Carcinoma of the Hepatobiliary Tract and Pancreas. Jpn J Clin Oncol. 2010;40(4):313–8.PubMedCrossRef

72.

Deutschbein T, Unger N, Yuece A, Eberhardt W, Gauler T, Lahner H, et al. Chemotherapy in Patients with Progressive, Undifferentiated Neuroendocrine Tumors: A Single-Center Experience. Horm Metab Res. 2011;43(12):838–43.PubMedCrossRef

73.

Patta A, Fakih M. First-line Cisplatin Plus Etoposide in High-grade Metastatic Neuroendocrine Tumors of Colon and Rectum (MCRC NET): Review of 8 Cases. ANTICANCER Res. 2011;975–978.

74.

Yamaguchi T, Machida N, Morizane C, Kasuga A, Takahashi H, Sudo K, et al. Multicenter retrospective analysis of systemic chemotherapy for advanced neuroendocrine carcinoma of the digestive system. Cancer Sci. 2014;105(9):1176–81.PubMedPubMedCentralCrossRef

75.

Walter T, Tougeron D, Baudin E, Le Malicot K, Lecomte T, Malka D, et al. Poorly differentiated gastro-entero-pancreatic neuroendocrine carcinomas: Are they really heterogeneous? Insights from the FFCD-GTE national cohort. Eur J Cancer. 2017;79:158–65.PubMedCrossRef

76.

Frizziero M, Spada F, Lamarca A, Kordatou Z, Barriuso J, Nuttall C, et al. Carboplatin in Combination with Oral or Intravenous Etoposide for Extra-Pulmonary. Poorly-Differentiated Neuroendocrine Carcinomas Neuroendocrinology. 2019;109(2):100–12.PubMed

77.

Alese OB, Jiang R, Shaib W, Wu C, Akce M, Behera M, et al. High-Grade Gastrointestinal Neuroendocrine Carcinoma Management and Outcomes: A National Cancer Database Study. Oncologist. 2020;25(5):e877.PubMedPubMedCentralCrossRef

78.

Jimenez-Fonseca P, La Salvia A, Capdevila J, Castaño A, Benavent M, Alonso-Orduña V, et al. Survival and prognostic factors analysis of 535 grade 3 gastroenteropancreatic neuroendocrine neoplasm (GEP-NEN): Data from the Spanish Taskforce of Neuroendocrine Tumours Registry (R-GETNE). Ann Oncol 2020 31 Suppl4 S711-S724 101016/annonc/annonc281.

79.

Hainsworth JD, Spigel DR, Litchy S, Greco FA. Phase II Trial of Paclitaxel, Carboplatin, and Etoposide in Advanced Poorly Differentiated Neuroendocrine Carcinoma: A Minnie Pearl Cancer Research Network Study. J Clin Oncol. 2006;24(22):3548–54.PubMedCrossRef

80.

A Phase II Study of Platinum-doublet Chemotherapy in Combination With Nivolumab as First-line Treatment in Subjects With Unresectable, Locally Advanced or Metastatic G3 Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin. (NCT03980925). Available from: https://clinicaltrials.gov.

81.

Ramella Munhoz R, de Mendonça Rego JF, de Celis Ferrari AR, Ignez Braghiroli M, Mendonça Bariani G, Hoff PM, et al. Combination of Irinotecan and a Platinum Agent for Poorly Differentiated Neuroendocrine Carcinomas. Rare tumors. 2013;5(3):135–9.CrossRef

82.

Okita NT, Kato K, Takahari D, Hirashima Y, Nakajima TE, Matsubara J, et al. Neuroendocrine tumors of the stomach: chemotherapy with cisplatin plus irinotecan is effective for gastric poorly-differentiated neuroendocrine carcinoma. Gastric Cancer. 2011;14(2):161–5.PubMedCrossRef

83.

Okuma HS, Iwasa S, Shoji H, Takashima A, Okita N, Honma Y, et al. Irinotecan plus Cisplatin in Patients with Extensive-Disease Poorly Differentiated Neuroendocrine Carcinoma of the Esophagus. ANTICANCER Res. 2014;34:5037–42.PubMed

84.

Nakano K, Takahashi S, Yuasa T, Nishimura N, Mishima Y, Sakajiri S, et al. Feasibility and Efficacy of Combined Cisplatin and Irinotecan Chemotherapy for Poorly Differentiated Neuroendocrine Carcinomas. Jpn J Clin Oncol. 2012;42(8):697–703.PubMedCrossRef

85.

Lu ZH, Li J, Lu M, Zhang XT, Li J, Zhou J, et al. Feasibility and efficacy of combined cisplatin plus irinotecan chemotherapy for gastroenteropancreatic neuroendocrine carcinomas. Med Oncol. 2013;30(3):664.PubMedCrossRef

86.

Mani MA, Shroff RT, Jacobs C, Wolff RA, Ajani JA, Yao JC, et al. A phase II study of irinotecan and cisplatin for metastatic or unresectable high grade neuroendocrine carcinoma. J Clin Oncol. 2008;26(15_suppl):15550–15550.

87.

A Randomized, Controlled Phase II Study to Compare Irinotecan Combined With Cisplatin (IP) Versus Etoposide Combined With Cisplatin (EP) in Advanced and Metastatic Gastrointestinal Pancreatic and Esophageal Neuroendocrine Carcinoma. (NCT03168594) Available from: https://clinicaltrials.gov.

88.

ECOG-ACRIN Cancer Research Group. Randomized Phase II Study of Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced G3 Non-small Cell Gastroenteropancreatic Neuroendocrine Carcinomas (NCT02595424). Available from: https://clinicaltrials.gov.

89.

Alifieris CE, Griniatsos J, Delis SG, Nikolaou M, Avgoustou C, Panagiotidis MI, et al. Capecitabine, Oxaliplatin, Irinotecan, and Bevacizumab Combination Followed by Pazopanib Plus Capecitabine Maintenance for High-Grade Gastrointestinal Neuroendocrine Carcinomas. Am J Clin Oncol. 2020;43(5):305–10.PubMedCrossRef

90.

Hentic O, Hammel P, Couvelard A, Rebours V, Zappa M, Palazzo M, et al. FOLFIRI regimen: an effective second-line chemotherapy after failure of etoposide-platinum combination in patients with neuroendocrine carcinomas grade 3. Endocr Relat Cancer. 2012;19(6):751–7.PubMedCrossRef

91.

Ferrarotto R, Testa L, Riechelmann RP, Sahade M, Siqueira LT, Costa FP, et al. Combination of Capecitabine and Oxaliplatin is an Effective Treatment Option for Advanced Neuroendocrine Tumors. Rare Tumors. 2013;5(3):121–5.CrossRef

92.

Hadoux J, Malka D, Planchard D, Scoazec JY, Caramella C, Guigay J, et al. Post-first-line FOLFOX chemotherapy for grade 3 neuroendocrine carcinoma. Endocr Relat Cancer. 2015;22(3):289–98.PubMedCrossRef

93.

Welin S, Sorbye H, Sebjornsen S, Knappskog S, Busch C, Öberg K. Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy. Cancer. 2011;117(20):4617–22.PubMedCrossRef

94.

Olsen IH, Sørensen JB, Federspiel B, Kjaer A, Hansen CP, Knigge U, et al. Temozolomide as Second or Third Line Treatment of Patients with Neuroendocrine Carcinomas. Sci World J. 2012;2012:1–4.CrossRef

95.

Kobayashi N, Takeda Y, Okubo N, Suzuki A, Tokuhisa M, Hiroshima Y, Ichikawa Y. Phase II study of temozolomide monotherapy in patients with extrapulmonary neuroendocrine carcinoma. Cancer Sci. 2021 Jan 16. https://doi.org/10.1111/cas.14811. Epub ahead of print. PMID: 33453146.

96.

McNamara MG, Frizziero M, Jacobs T, Lamarca A, Hubner RA, Valle JW, et al. Second-line treatment in patients with advanced extra-pulmonary poorly differentiated neuroendocrine carcinoma: a systematic review and meta-analysis. Ther Adv Med Oncol. 2020;12:1–14.CrossRef

97.

A Randomized Phase II Trial of Capecitabine and Temozolomide (CAPTEM) or FOLFIRI as SEcond-line Therapy in NEuroendocrine CArcinomas and Exploratory Analysis of Predictive Role of Positron Emission Tomography (PET) Imaging and Biological Markers (NCT03387592). Available from: https://clinicaltrials.gov.

98.

Assessment of the Efficacy of Bevacizumab in Combination With Folfiri as Second-line Treatment After the Failure of the Cisplatin (or Carboplatin)-Etoposide Combination in Patients Suffering From an Advanced Inoperable Poorly Differentiated Neuroendocrine Carcinoma of an Unknown or Gastroentero-pancreatic Primary Cancer. A Phase 2 Non-comparative Randomized Study (NCT02820857). Available from: https://clinicaltrials.gov.

99.

Craig Z, Swain J, Batman E, Wadsley J, Reed N, Faluyi O, et al. NET-02 trial protocol: a multicentre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (NEC). BMJ Open. 2020;10(2):e034527.PubMedPubMedCentralCrossRef

100.

Jimenez-Fonseca P, Alonso V, Hernando J, Lopez C, La Salvia A, Crespo G, et al. Análisis de supervivencia y factores pronósticos en carcinomas neuroendocrinos gastroenteropancreáticos: datos de 601 pacientes de resgistro R-GETNE. Libro Comun Congr Virtual SEOM 2020. ePóster 443:488–9.

101.

NCCN Clinical practice guidelines in oncology. Neuroendocrine and adrenal tumors, version 2. 2020. Available at: https://nccn.org.

102.

Caplin ME, Baudin E, Ferolla P, Filosso P, Garcia-Yuste M, Lim E, et al. Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. Ann Oncol. 2015;26(8):1604–20.PubMedCrossRef

103.

Kunz PL, Reidy-Lagunes D, Anthony LB, Bertino EM, Bredtro K, Chan JA, et al. Consensus Guidelines for the management and treatment of neuroendocrine tumors. Pancreas. 2013;42(4):557–77.

104.

Baudin E, Caplin M, Garcia-Carbonero R, Fazio N, Ferolla P, Filosso PL, et al. ESMO Guidelines Committee. Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021:S0923-7534(21)00011-9.

105.

Nussbaum DP, Speicher PJ, Gulack BC, Hartwig MG, Onaitis MW, D’Amico TA, et al. Defining the Role of Adjuvant Chemotherapy After Lobectomy for Typical Bronchopulmonary Carcinoid Tumors. Ann Thorac Surg. 2015;99(2):428–34.PubMedCrossRef

106.

Marcondes W, Samer A, Konstatinos L, Ragnar H, R M. Impact of adjuvant chemotherapy in non-metastatic node positive bronchial neuroendocrine tumors (BNET). J Clin Oncol. 2017;35(15_suppl):8533–8533.

107.

Westin G, Alsidawi S, Leventakos K, Halfdanarson T, Molina J. Impact of adjuvant chemotherapy in non-metastatic node positive bronchial neuroendocrine tumors (BNET). J Clin Oncol. 2017;35(15_suppl):8533–8533.

108.

Steuer CE, Behera M, Kim S, et al. Atypical carcinoid tumor of the lung: a surveillance, epidemiology, and end results database analysis. J Thorac Oncol. 2015;10:479–85.PubMedCrossRef

109.

Anderson KL, Mulvihill MS, Speicher PJ, et al. Adjuvant Chemotherapy Does Not Confer Superior Survival in Patients With Atypical Carcinoid Tumors. Ann Thorac Surg. 2017;104:1221–30.PubMedPubMedCentralCrossRef

110.

Daddi N, Schiavon M, Filosso PL, et al. Multi-Institutional Italian Pathology Group: Prognostic factors in a multicentre study of 247 atypical pulmonary carcinoids. Eur J Cardiothorac Surg. 2014;45:677–86.PubMedCrossRef

111.

Gaur P, Leary C, Yao JC et al. Thymic neuroendocrine tumors: a SEER database analysis of 160 patients. Ann. Surg. 2010;251:1117–1121.

112.

Filosso PL, Yao X, Ahmad U, et al. Outcome of primary neuroendocrine tumors of the thymus: a joint analysis of the International Thymic Malignancy Interest Group and the European Society of Thoracic Surgeons databases. J Thorac Cardiovasc Surg. 2015;149:103–9.PubMedCrossRef

113.

Sullivan JL, Weksler B. Neuroendocrine Tumors of the Thymus: Analysis of Factors Affecting Survival in 254 Patients. Ann Thorac Surg. 2017;103:935–9.PubMedCrossRef

114.

Zhao Y, Gu H, Fan L, et al. Comparison of clinical features and survival between thymic carcinoma and thymic carcinoid patients. Eur J Cardiothorac Surg. 2017;52:33–8.PubMedCrossRef

115.

Pavel M, O’Toole D, Costa F, Capdevila J, Gross D, Kianmanesh R, et al. ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site. Neuroendocrinology. 2016;103(2):172–85.PubMedCrossRef

116.

Pavel M, Öberg K, Falconi M, Krenning EP, Sundin A, Perren A, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(7):844–60.PubMedCrossRef

117.

Nordic and Childs A, Kirkwood A, Edeline J, Luong TV, Watkins J, Lamarca A, et al. Ki-67 index and response to chemotherapy in patients with neuroendocrine tumours. Endocr Relat Cancer. 2016;23(7):563–70.

118.

Hijioka S, Hosoda W, Matsuo K, Ueno M, Furukawa M, Yoshitomi H, et al. Rb Loss and KRAS Mutation Are Predictors of the Response to Platinum-Based Chemotherapy in Pancreatic Neuroendocrine Neoplasm with Grade 3: A Japanese Multicenter Pancreatic NEN-G3 Study. Clin Cancer Res. 2017;23(16):4625–32.PubMedCrossRef

119.

Pilié PG, Tang C, Mills GB, Yap TA. State-of-the-art strategies for targeting the DNA damage response in cancer. Nat Rev Clin Oncol. 2019;16(2):81–104.PubMedPubMedCentralCrossRef

120.

Hegi ME, Diserens AC, Gorlia T, Hamou MF, de tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352(10):997–1003.PubMedCrossRef

121.

de Mestier L, Couvelard A, Blazevic A, Hentic O, de Herder WW, Rebours V, et al. Critical appraisal of MGMT in digestive NET treated with alkylating agents. Endocrine-Related Cancer. 2020;27(10):R391–405.PubMedCrossRef

122.

Korse CM, Taal BG, van Velthuysen ML, Visser O. Incidence and survival of neuroendocrine tumours in the Netherlands according to histological grade: experience of two decades of cancer registry. Eur J Cancer. 2013;49(8):1975–83.PubMedCrossRef

123.

Rekhtman N, Pietanza MC, Hellmann MD, Naidoo J, Arora A, Won H, et al. Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma-like and Non-Small Cell Carcinoma-like Subsets. Clin Cancer Res. 2016;22(14):3618–29.PubMedPubMedCentralCrossRef

124.

Capdevila J, Arqués O, Hernández Mora JR, Matito J, Caratù G, Mancuso FM, et al. Epigenetic EGFR Gene Repression Confers Sensitivity to Therapeutic BRAFV600E Blockade in Colon Neuroendocrine Carcinomas. Clin Cancer Res. 2020;26(4):902–909.PubMedCrossRef

125.

Klempner SJ, Gershenhorn B, Tran P, Lee TK, Erlander MG, Gowen K, et al. BRAFV600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy. Cancer Discov. 2016;6(6):594–600.PubMedPubMedCentralCrossRef

126.

Sahnane N, Furlan D, Monti M, Romualdi C, Vanoli A, Vicari E, et al. Microsatellite unstable gastrointestinal neuroendocrine carcinomas: a new clinicopathologic entity. Endocr Relat Cancer. 2015;22(1):35–45.PubMedCrossRef

127.

Lemery S, Keegan P, Pazdur R. First FDA Approval Agnostic of Cancer Site — When a Biomarker Defines the Indication. N Engl J Med. 2017;377(15):1409–12.PubMedCrossRef

128.

Huang FW, Feng FY. A Tumor-Agnostic NTRK (TRK) Inhibitor. Cell. 2019;177(1):8.PubMedCrossRef

129.

FDA Approves Entrectinib for NTRK-Fusion Cancers, ROS1-Positive NSCLC - The ASCO Post 2020. Available at: https://www.ascopost.com/News/60351.

130.

Marabelle A, Fakih M, Lopez J, Shah M, Shapira-Frommer R, Nakagawa K, et al. Association of tumour mutational burden with outcomes in patients with select advanced solid tumors treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020;21(10):1353–65.PubMedCrossRef

Title: Chemotherapy in NEN: still has a role?
Authors: Paula Espinosa-Olarte
Anna La Salvia
Maria C. Riesco-Martinez
Beatriz Anton-Pascual
Rocio Garcia-Carbonero
Publication date: 01-09-2021
Publisher: Springer US
Keywords: Carcinoid Tumor
Bevacizumab
Neuroendocrine Tumor
Cytostatic Therapy
Everolimus
Published in: Reviews in Endocrine and Metabolic Disorders / Issue 3/2021
Print ISSN: 1389-9155
Electronic ISSN: 1573-2606
DOI: https://doi.org/10.1007/s11154-021-09638-0

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Chemotherapy in NEN: still has a role?

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2021

PRRT: identikit of the perfect patient

Update in carcinoid heart disease - the heart of the matter

Classification of neuroendocrine neoplasms: lights and shadows

Foreword to the special issue on advances in neuroendocrine neoplasms

Evaluating cost-effectiveness in the management of neuroendocrine neoplasms

Epigenetic regulation of somatostatin and somatostatin receptors in neuroendocrine tumors and other types of cancer

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page